159 related articles for article (PubMed ID: 21371544)
1. DC-SIGN mediated antigen-targeting using glycan-modified liposomes: formulation considerations.
Joshi MD; Unger WW; van Beelen AJ; Bruijns SC; Litjens M; van Bloois L; Kalay H; van Kooyk Y; Storm G
Int J Pharm; 2011 Sep; 416(2):426-32. PubMed ID: 21371544
[TBL] [Abstract][Full Text] [Related]
2. Glycan-modified liposomes boost CD4+ and CD8+ T-cell responses by targeting DC-SIGN on dendritic cells.
Unger WW; van Beelen AJ; Bruijns SC; Joshi M; Fehres CM; van Bloois L; Verstege MI; Ambrosini M; Kalay H; Nazmi K; Bolscher JG; Hooijberg E; de Gruijl TD; Storm G; van Kooyk Y
J Control Release; 2012 May; 160(1):88-95. PubMed ID: 22366522
[TBL] [Abstract][Full Text] [Related]
3. Targeting glycan modified OVA to murine DC-SIGN transgenic dendritic cells enhances MHC class I and II presentation.
Singh SK; Stephani J; Schaefer M; Kalay H; García-Vallejo JJ; den Haan J; Saeland E; Sparwasser T; van Kooyk Y
Mol Immunol; 2009 Dec; 47(2-3):164-74. PubMed ID: 19818504
[TBL] [Abstract][Full Text] [Related]
4. Cross-presentation through langerin and DC-SIGN targeting requires different formulations of glycan-modified antigens.
Fehres CM; Kalay H; Bruijns SC; Musaafir SA; Ambrosini M; van Bloois L; van Vliet SJ; Storm G; Garcia-Vallejo JJ; van Kooyk Y
J Control Release; 2015 Apr; 203():67-76. PubMed ID: 25656175
[TBL] [Abstract][Full Text] [Related]
5. Glycan-based DC-SIGN targeting vaccines to enhance antigen cross-presentation.
van Kooyk Y; Unger WW; Fehres CM; Kalay H; García-Vallejo JJ
Mol Immunol; 2013 Sep; 55(2):143-5. PubMed ID: 23158834
[TBL] [Abstract][Full Text] [Related]
6. Targeted PLGA nano- but not microparticles specifically deliver antigen to human dendritic cells via DC-SIGN in vitro.
Cruz LJ; Tacken PJ; Fokkink R; Joosten B; Stuart MC; Albericio F; Torensma R; Figdor CG
J Control Release; 2010 Jun; 144(2):118-26. PubMed ID: 20156497
[TBL] [Abstract][Full Text] [Related]
7. C-type lectins on dendritic cells: key modulators for the induction of immune responses.
van Kooyk Y
Biochem Soc Trans; 2008 Dec; 36(Pt 6):1478-81. PubMed ID: 19021579
[TBL] [Abstract][Full Text] [Related]
8. In vivo targeting of antigens to human dendritic cells through DC-SIGN elicits stimulatory immune responses and inhibits tumor growth in grafted mouse models.
Kretz-Rommel A; Qin F; Dakappagari N; Torensma R; Faas S; Wu D; Bowdish KS
J Immunother; 2007 Oct; 30(7):715-26. PubMed ID: 17893564
[TBL] [Abstract][Full Text] [Related]
9. In vivo targeting of DC-SIGN-positive antigen-presenting cells in a nonhuman primate model.
Pereira CF; Torensma R; Hebeda K; Kretz-Rommel A; Faas SJ; Figdor CG; Adema GJ
J Immunother; 2007 Oct; 30(7):705-14. PubMed ID: 17893563
[TBL] [Abstract][Full Text] [Related]
10. The influence of PEG chain length and targeting moiety on antibody-mediated delivery of nanoparticle vaccines to human dendritic cells.
Cruz LJ; Tacken PJ; Fokkink R; Figdor CG
Biomaterials; 2011 Oct; 32(28):6791-803. PubMed ID: 21724247
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells recognize tumor-specific glycosylation of carcinoembryonic antigen on colorectal cancer cells through dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin.
van Gisbergen KP; Aarnoudse CA; Meijer GA; Geijtenbeek TB; van Kooyk Y
Cancer Res; 2005 Jul; 65(13):5935-44. PubMed ID: 15994972
[TBL] [Abstract][Full Text] [Related]
12. Comparative analysis reveals selective recognition of glycans by the dendritic cell receptors DC-SIGN and Langerin.
Holla A; Skerra A
Protein Eng Des Sel; 2011 Sep; 24(9):659-69. PubMed ID: 21540232
[TBL] [Abstract][Full Text] [Related]
13. Neutrophils mediate immune modulation of dendritic cells through glycosylation-dependent interactions between Mac-1 and DC-SIGN.
van Gisbergen KP; Sanchez-Hernandez M; Geijtenbeek TB; van Kooyk Y
J Exp Med; 2005 Apr; 201(8):1281-92. PubMed ID: 15837813
[TBL] [Abstract][Full Text] [Related]
14. The dendritic cell-specific C-type lectin DC-SIGN is a receptor for Schistosoma mansoni egg antigens and recognizes the glycan antigen Lewis x.
van Die I; van Vliet SJ; Nyame AK; Cummings RD; Bank CM; Appelmelk B; Geijtenbeek TB; van Kooyk Y
Glycobiology; 2003 Jun; 13(6):471-8. PubMed ID: 12626400
[TBL] [Abstract][Full Text] [Related]
15. DC-SIGN: escape mechanism for pathogens.
van Kooyk Y; Geijtenbeek TB
Nat Rev Immunol; 2003 Sep; 3(9):697-709. PubMed ID: 12949494
[TBL] [Abstract][Full Text] [Related]
16. Glycan modification of the tumor antigen gp100 targets DC-SIGN to enhance dendritic cell induced antigen presentation to T cells.
Aarnoudse CA; Bax M; Sánchez-Hernández M; García-Vallejo JJ; van Kooyk Y
Int J Cancer; 2008 Feb; 122(4):839-46. PubMed ID: 17957800
[TBL] [Abstract][Full Text] [Related]
17. Measles virus targets DC-SIGN to enhance dendritic cell infection.
de Witte L; Abt M; Schneider-Schaulies S; van Kooyk Y; Geijtenbeek TB
J Virol; 2006 Apr; 80(7):3477-86. PubMed ID: 16537615
[TBL] [Abstract][Full Text] [Related]
18. In situ Delivery of Antigen to DC-SIGN(+)CD14(+) Dermal Dendritic Cells Results in Enhanced CD8(+) T-Cell Responses.
Fehres CM; van Beelen AJ; Bruijns SCM; Ambrosini M; Kalay H; Bloois LV; Unger WWJ; Garcia-Vallejo JJ; Storm G; de Gruijl TD; Kooyk YV
J Invest Dermatol; 2015 Sep; 135(9):2228-2236. PubMed ID: 25885805
[TBL] [Abstract][Full Text] [Related]
19. Interactions of DC-SIGN with Mac-1 and CEACAM1 regulate contact between dendritic cells and neutrophils.
van Gisbergen KP; Ludwig IS; Geijtenbeek TB; van Kooyk Y
FEBS Lett; 2005 Nov; 579(27):6159-68. PubMed ID: 16246332
[TBL] [Abstract][Full Text] [Related]
20. Activation of human monocyte-derived dendritic cells by Burkholderia pseudomallei does not require binding to the C-type lectin DC-SIGN.
Charoensap J; Engering A; Utaisincharoen P; van Kooyk Y; Sirisinha S
Trans R Soc Trop Med Hyg; 2008 Dec; 102 Suppl 1():S76-81. PubMed ID: 19121694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
